AR013094A1 - N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES - Google Patents
N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINESInfo
- Publication number
- AR013094A1 AR013094A1 ARP980102858A ARP980102858A AR013094A1 AR 013094 A1 AR013094 A1 AR 013094A1 AR P980102858 A ARP980102858 A AR P980102858A AR P980102858 A ARP980102858 A AR P980102858A AR 013094 A1 AR013094 A1 AR 013094A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- compounds
- alkyl
- independently selected
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuestos de urea N-sustituida que comprenden la formula (I) o una sal o solvato farmacéuticamente aceptable del mismo, en donde: A representa N oN-oxido; X representa N, CH o C, de manera que cuando X es N o CH, hay un unico enlace alátomo de carbono 11 segun se representa por la línea solida; ocuando X es C, hay un doble enlace al átomo de carbono 11, segun se representa por las líneas punteada y solida; X1 y X2 son independientemente seleccionadosentre bromo o cloro, y X3 yX4 son independientemente seleccionados, bromo o cloro siempre que por lo menos uno de X3 y X4 sea hidrogeno; Y1 e Y2 sonindependientemente seleccionados entre hidrogeno o alquilo; Z es =O o =S; R5, R6, R7 y R8 cada uno independientementehidrogeno, -C F3, -COR10, alquilo oarilo, y adicionalmente en donde R5 puede combinarse con R6 para representar =O o =S y/o R7 puede combinarse con R8 para representar =O o =S; R10, R19 yR20 representan independientemente hidrogeno, alquilo,alcoxi, arilo,aralq uilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo,heterocicloalquilo y heterocicloalquilalquilo, con la condicion de que R19 y R20 no sean ambos hidrogeno; v es cero, 1, 2 o 3; y W es cero o1;composiciones farmacéuticas que s on inhibidores de la enzima, transferasa de proteína farnesilo y uso de dichos compuestos para preparar medicamentos utilespara inhibir el crecimiento anormal de células.N-substituted urea compounds comprising formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: A represents N or N-oxide; X represents N, CH or C, so that when X is N or CH, there is a single carbon 11 atom bond as represented by the solid line; When X is C, there is a double bond to carbon atom 11, as represented by the dotted and solid lines; X1 and X2 are independently selected from bromine or chlorine, and X3 and X4 are independently selected from bromine or chlorine provided that at least one of X3 and X4 is hydrogen; Y1 and Y2 are independently selected from hydrogen or alkyl; Z is = O or = S; R5, R6, R7 and R8 each independently hydrogen, -C F3, -COR10, alkyl or aryl, and further wherein R5 may be combined with R6 to represent = O or = S and / or R7 may be combined with R8 to represent = O or = S; R10, R19 and R20 independently represent hydrogen, alkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl and heterocycloalkylalkyl, provided that R19 and R20 are not both hydrogen; v is zero, 1, 2, or 3; and W is zero or 1, pharmaceutical compositions that are inhibitors of the enzyme, farnesyl protein transferase and use of said compounds to prepare useful drugs to inhibit abnormal cell growth.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87704997A | 1997-06-17 | 1997-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013094A1 true AR013094A1 (en) | 2000-12-13 |
Family
ID=25369144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102858A AR013094A1 (en) | 1997-06-17 | 1998-06-16 | N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0989979A1 (en) |
| JP (1) | JP2002506444A (en) |
| KR (1) | KR20010013881A (en) |
| CN (1) | CN1267291A (en) |
| AR (1) | AR013094A1 (en) |
| AU (1) | AU8253598A (en) |
| CA (1) | CA2293706C (en) |
| CO (1) | CO4940458A1 (en) |
| HU (1) | HUP0002954A3 (en) |
| IL (1) | IL133389A0 (en) |
| NZ (1) | NZ501571A (en) |
| PE (1) | PE82799A1 (en) |
| WO (1) | WO1998057948A1 (en) |
| ZA (1) | ZA985205B (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| AU1186202A (en) | 2000-10-05 | 2002-04-15 | George Q Daley | Methods of inducing cancer cell death and tumor regression |
| US7820673B2 (en) * | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| MX364438B (en) * | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Covalent inhibitors of kras g12c. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| BR112017021869A2 (en) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | substituted quinazoline compounds and methods of use thereof |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
| CN108779097A (en) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | Include the quinazoline compound and its application method of the 2- substitutions of substituted heterocycle |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110036010A (en) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | The inhibitor of KRAS G12C mutain |
| JP2019534260A (en) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Heterocyclic compounds as inhibitors of RAS and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| EP3630745A2 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Covalent inhibitors of kras |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN111960990A (en) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | Auxiliary agent and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them |
| AU730194B2 (en) * | 1995-12-22 | 2001-03-01 | Merck Sharp & Dohme Corp. | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
| KR20000036103A (en) * | 1996-09-13 | 2000-06-26 | 둘락 노먼 씨. | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase |
| SK33699A3 (en) * | 1996-09-13 | 2000-03-13 | Schering Corp | Tricyclic compounds useful for inhibition of farnesyl protein transferase |
-
1998
- 1998-06-15 KR KR1019997011903A patent/KR20010013881A/en not_active Application Discontinuation
- 1998-06-15 NZ NZ501571A patent/NZ501571A/en unknown
- 1998-06-15 AU AU82535/98A patent/AU8253598A/en not_active Abandoned
- 1998-06-15 CN CN98808189A patent/CN1267291A/en active Pending
- 1998-06-15 HU HU0002954A patent/HUP0002954A3/en unknown
- 1998-06-15 JP JP50450299A patent/JP2002506444A/en not_active Ceased
- 1998-06-15 EP EP98932717A patent/EP0989979A1/en not_active Withdrawn
- 1998-06-15 WO PCT/US1998/011507 patent/WO1998057948A1/en not_active Application Discontinuation
- 1998-06-15 ZA ZA985205A patent/ZA985205B/en unknown
- 1998-06-15 CA CA002293706A patent/CA2293706C/en not_active Expired - Fee Related
- 1998-06-15 PE PE1998000506A patent/PE82799A1/en not_active Application Discontinuation
- 1998-06-15 IL IL13338998A patent/IL133389A0/en unknown
- 1998-06-16 AR ARP980102858A patent/AR013094A1/en unknown
- 1998-06-16 CO CO98034144A patent/CO4940458A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010013881A (en) | 2001-02-26 |
| IL133389A0 (en) | 2001-04-30 |
| CO4940458A1 (en) | 2000-07-24 |
| AU8253598A (en) | 1999-01-04 |
| CA2293706C (en) | 2008-11-18 |
| PE82799A1 (en) | 1999-08-26 |
| EP0989979A1 (en) | 2000-04-05 |
| JP2002506444A (en) | 2002-02-26 |
| WO1998057948A1 (en) | 1998-12-23 |
| ZA985205B (en) | 1998-12-15 |
| NZ501571A (en) | 2002-02-01 |
| CN1267291A (en) | 2000-09-20 |
| CA2293706A1 (en) | 1998-12-23 |
| HUP0002954A3 (en) | 2002-11-28 |
| HUP0002954A2 (en) | 2001-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013094A1 (en) | N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES | |
| AR029216A1 (en) | NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE | |
| AR017796A1 (en) | DERIVATIVES OF 2-ARIL-8-OXODIHIDROPURINE, PROCEDURES TO PREPARE THEM, INTERMEDIATE APPLICATION COMPOUNDS IN THESE PROCEDURES, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF STATES OF STATE. | |
| DK0650476T3 (en) | Peripheral vasodilating agent containing N-acylated 4-aminopiperidine derivatives as active ingredients | |
| TR199902203T2 (en) | 1,8-anele quinolinone derivatives substituted with fernesyl transferase inhibitor, N- or C-linked imidazoles. | |
| DK365184D0 (en) | 1,8-NAPHTHYRIDINE DERIVATIVES OR ESTERS OR SALTS THEREOF, THEIR PREPARATION AND USE AS PHARMACEUTICALS | |
| AR012781A1 (en) | ALPHA-KETOAMIDE 20S PROTEOSOME INHIBITORS. | |
| AR003936A1 (en) | TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT USEFUL TO INHIBIT ABNORMAL GROWTH OF CELLS. | |
| ES2195034T3 (en) | METALOPROTEINASE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING THIS INHIBITOR AND ITS PHARMACEUTICAL USE, AND PROCEDURES THAT SERVE FOR PREPARATION. | |
| PE20011001A1 (en) | HETEROCYCLIC COMPOUNDS AS SODIUM / PROTON EXCHANGE INHIBITORS | |
| BR0010476A (en) | Compounds derived from 4,5,6,7-tetrahydroindazole and their use as antitumor agents | |
| ES2196772T3 (en) | AMINO CYCLES COMPOUNDS. | |
| HUP0400579A2 (en) | Tetralone derivatives as antitumor agents, process for their preparation and pharmaceutical compositions containing them | |
| CO5570660A2 (en) | MODIFIED C-6 INDAZOLILPIRROLOTRIAZINAS | |
| ES2196806T3 (en) | DERIVATIVES OF FENILUREA AND FENILTIOUREA. | |
| HUP0400694A2 (en) | Small molecule inhibitors of rotamase enzyme activity and pharmaceutical compositions containing the compounds | |
| HUP0000121A2 (en) | Tricyclic inhibitors of farnesyl protein transferase, pharmaceutical compositions containing them and their use | |
| DK0928788T3 (en) | Imidazolidin-4-one derivatives useful as anticancer agents | |
| FR2599740B1 (en) | BENZO (B) THIOPHENE DERIVATIVES OF BENZO (B) FURANNECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | |
| AR020165A1 (en) | DERIVATIVES OF REPLACED PYRIMIDINS, ITS PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF THEM FOR THE PREPARATION OF MEDICINES | |
| NO20000722L (en) | 2- (4-aryl or heteroaryl-piperazin-1-ylmethyl) -1H-indole derivatives | |
| DK39286A (en) | IMIDAZOLD DERIVATIVES, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES | |
| CO5080750A1 (en) | BENZIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS ANTHROMBORTIC | |
| PE20040750A1 (en) | DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 | |
| AR041218A1 (en) | DERIVADOS DE INDOLILO, A PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |